Astellas pays $165mm up front to acquire IO partner Potenza
Following a successful three-and-a-half-year partnership, Astellas Pharma Inc. exercised its option to acquire Potenza Therapeutics Inc. for $164.6mm in cash and possibly another $240.1mm tied to development milestones.
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.